Project description:The objective of the sudy is to evalute the role of mTORC1 signalling in the regulation of the metabolism of MOLM-14 cells. We used microarrays to investigate gene expression in MOLM-14 cells after down-regulation of mTORC1 signalling by rapamycin.
Project description:Development and evaluation of an autosampler for integrating nanoPOTS with LC-MS. Includes proteomic data from nanoPOTS-based sample preparation, including diluted peptides of Shewanella oneidensis MR-1, single cultured MCF10A cells, and single cells from three Acute Myeloid Leukemia (AML) cell lines (MOLM-14, K562, and CMK). Data was searched with MaxQuant.
Project description:AMPK activation by GSK621 induces cell death in acute myeloid leukemia. Surprisingly, we found that mTORC1 inhibition with rapamycin protects cells against GSK621-induced cytotoxicity. A genome-wide gene expression assay was performed to understand the molecular basis of this phenotype.
Project description:Expression data from MOLM-14 human acute myeloid leukemia cell line after AMPK activation by GSK621 according to mTORC1 activation level
Project description:To explore the function of Mitochondrial Fission 1 (FIS1) in acute myeloid leukemia (AML), we used shRNA to knock down the expression of FIS1 in leukemia cell line MOLM-13 cells and performed RNA-seq experiments to profile transcriptional changes upon FIS1 depletion.
Project description:The human acute myeloid leukemia cell lines MOLM-14 and THP-1 were silenced for MUC1 expression by lentiviral transduction of MUC1 specific shRNA or scrambled control. RNA was extracted and NanoString array for microRNAs was performed.
Project description:MOLM-13 acute myeloid leukemia cells were treated with 3 µM FIDAS-5 methionine S-adenosyltransferase 2A (MAT2A) inhibitor or 0.1% DMSO as control for 48 hours
Project description:The METTL3 methyltransferase is responsible for the deposition of N6-methyladenosine (m6A) modifications in RNA and has been identified as essential for survival and proliferation of acute myeloid leukemia (AML) cells in a genome-wide CRISPR screen. In our experiments involving a small-molecule METTL3 inhibitor (UZH2) in the AML cell line MOLM-13, we observed suppression of cell proliferation, induction of apoptosis and differentiation. The aim of RNA-seq experiment was to characterize the transcriptomic changes occurring in MOLM-13 cell line after treatment UZH2. Cell were treated with 10 µM of UZH2 for 16 h and compered to untreated controls (5 % DMSO).
Project description:Chromatin immunoprecipitation with specific isolation of chromatin associated proteins (ChIP-SICAP) was used to identify chromatin-bound interactors of CEBPA and RUNX1 in the 3q-rearranged human myeloid leukemia cell line MOLM-1.
